enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. Long-acting beta-adrenoceptor agonist - Wikipedia

   en.wikipedia.org/wiki/Long-acting_beta...

   This second medication in this combination is the synthetic inhaled corticosteroid fluticasone furoate. This product was approved by the FDA in May 2013 as once-daily inhaled therapy for the treatment of chronic obstructive pulmonary disease (COPD) with umeclidinium bromide: Anoro Ellipta.

3. Fluticasone furoate/umeclidinium bromide/vilanterol - Wikipedia

   en.wikipedia.org/wiki/Fluticasone_furoate/...

   Fluticasone furoate/umeclidinium bromide/vilanterol, sold under the brand name Trelegy Ellipta among others, is a fixed-dose combination inhaled medication that is used for the maintenance treatment of chronic obstructive pulmonary disease (COPD). [6] [7] The medications work in different ways: fluticasone furoate is an inhaled corticosteroid ...

4. Beta2-adrenergic agonist - Wikipedia

   en.wikipedia.org/wiki/Beta2-adrenergic_agonist

   Bronchodilators are considered an important treatment regime for chronic obstructive pulmonary disease (COPD) and are usually used in combination with short acting medications and long acting medications in a combined inhaler. [1] [2]

5. Metered-dose inhaler - Wikipedia

   en.wikipedia.org/wiki/Metered-dose_inhaler

   The medication in a metered dose inhaler is most commonly a bronchodilator, corticosteroid or a combination of both for treating asthma and COPD. Other medications less commonly used but also administered by MDI are mast cell stabilizers, such as cromoglicate or nedocromil .

6. Inhaler - Wikipedia

   en.wikipedia.org/wiki/Inhaler

   An inhaler (puffer, asthma pump or allergy spray) is a medical device used for delivering medicines into the lungs through the work of a person's breathing. This allows medicines to be delivered to and absorbed in the lungs, which provides the ability for targeted medical treatment to this specific region of the body, as well as a reduction in the side effects of oral medications.

7. AstraZeneca to cap US out-of-pocket costs for inhalers ... - AOL

   www.aol.com/news/astrazeneca-cap-us-pocket-costs...

   The cap would apply to all its respiratory products portfolio, including inhalers to treat asthma and chronic obstructive pulmonary disease (COPD), AstraZeneca said. Boehringer had also said it ...